This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kozak, S. Articles by Fleisch, H. Search for Related Content PubMed PubMed Citation Articles by Kozak, S. Articles by Fleisch, H.

Effect of a Single Injection of Two New Bisphosphonates on the Hypercalcemia and Hypercalciuria Induced by Walker Carcinosarcoma 256/B in Thyroparathyroidectomized Rats¹

Department of Pathophysiology, University of Berne, Murtenstrasse 35, CH-3010 Berne, Switzerland

The effect of one single injection of two new bisphosphonates, 4-amino-1-hydroxybutylidene-1,1-bisphosphonate and 2-(2-pyridyl)ethylidene-1,1-bisphosphonate, and of dichloromethylenebisphosphonate on the hypercalcemia and hypercalciuria induced by the Walker carcinosarcoma 256/B in the thyroparathyroidectomized rat was evaluated. When given either before or after the development of hypercalcemia and hypercalciuria, 16.1 µmol/kg 4-amino-1-hydroxybutylidene-1,1-bisphosphonate or 2-(2-pyridyl)ethylidene-1,1-bisphosphonate totally inhibited hypercalciuria, whereas hypercalcemia was only partially reduced over the 14 days of the experiment. At 10 and 100 times lower doses, the effect was strongest the first days, but still partially present 14 days later. The difference of activity on calcemia and calciuria appears to be due to the fact that the tumor increased both bone resorption and renal reabsorption of calcium. Only the former was altered by the bisphosphonates. The two new compounds appeared to be of similar potency and more active than dichloromethylenebisphosphonate. These compounds could be promising for the treatment of malignant hypercalcemia and other conditions with increased bone resorption in humans, even when given only over short periods of time.

¹ This work was supported by the Swiss National Science Foundation (Grant 3.880-85); by the Procter & Gamble Company, Cincinnati, OH; and by Gentili S.p.A., Pisa, Italy.

² To whom requests for reprints should be addressed, at Division of Pathophysiology, Department of Medicine, University Hospital, 1211 Geneva 4, Switzerland.

Received 1/22/87. Revised 6/18/87. Accepted 8/14/87.